Inmune Bio Prices $4.5M Stock Sale at $1.50 With Matching Warrant Package
INMB sits 39% above its 52-week low of $1.09.
Summary
Inmune Bio priced a $4.5 million sale of 3,000,000 shares at $1.50, bundled with 3,000,000 warrants at a $1.65 strike, netting about $4.0 million for CORDStrom development and working capital.
Key Events · Financing and Capital Events · INMB
-
Priced $4.5M Stock and Warrant Deal
3,000,000 shares sold at $1.50 for $4,500,000 gross, plus a concurrent private placement of 3,000,000 warrants at a $1.65 exercise price — 100% warrant coverage.
-
Net Proceeds About $4.0 Million
A.G.P. takes a 7.0% cash fee of $315,000, leaving $4,185,000 before expenses and roughly $4.0 million net. Full warrant exercise would add about $4.95 million more.
-
Immediate $0.67 Per Share Dilution
Pro forma as adjusted net tangible book value rises to $0.83 per share from $0.78, so buyers at $1.50 absorb $0.67 of dilution; shares outstanding go to 30,959,079 from 27,959,079.
-
Cash Covers Only a Short Runway
Pro forma cash of $23,751,000 versus $18,411,000 actual at June 30, 2026, against a going-concern warning previously disclosed in the Q2 2026 10-Q.
Analysis · INMB · Life Sciences
Inmune Bio is raising $4.5 million gross by selling 3,000,000 shares at $1.50, and the single healthcare-focused investor also receives 3,000,000 warrants struck at $1.65 that become exercisable in April 2027. Net proceeds of roughly $4.0 million land against $18.4 million of cash at June 30, 2026 and a going-concern warning previously disclosed in the Q2 10-Q — this buys months, not years, ahead of the February 2027 UK MAA filing. The cost is real: new buyers take $0.67 per share of immediate net tangible book value dilution, and full warrant exercise would add another $4.95 million and 3,000,000 shares. The 7.0% placement fee and 60-day insider lock-up are standard for a deal this size.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.5M. The 52-week trading range was $1.09 to $2.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.